Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin

This article was originally published in The Pink Sheet Daily

Executive Summary

Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.

Advertisement

Related Content

PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
Merck's IMPROVE-IT Study: Will Missing Data, Subgroups Hinder Zetia CV Claim?
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register